Importantly, this suppression is also glucose-dependentglucagon responses to hypoglycemia remain intact, preserving a critical protective mechanism
J Biol Chem 280:3492434932 Acknowledgments The work performed in the authors laboratory was supported by the Swedish Research Council, LUA/ALF from the Sahlgrenska University Hospital and Edit Jacobsons Foundation
Like other incretin-based medications, the most common side effects were gastrointestinal: Common Side Effects Nausea: Reported in approximately 25-45% of participants depending on dose (most common during titration) Diarrhea: Approximately 20-35% of participants Vomiting: Approximately 10-20% of participants Constipation: Approximately 10-15% of participants Decreased appetite: Common and expected given the mechanism of action Less Common but Notable Effects Increased heart rate: Small elevations in resting heart rate were observed, consistent with other GLP-1 class medications Injection site reactions: Mild redness or itching at injection sites Fatigue: Reported by some participants, particularly during dose escalation Most adverse events were mild to moderate and occurred primarily during the dose escalation phase
Nutritional adequacy becomes particularly important during GLP-1 therapy
SURMOUNT-OSA showed AHI reduction of about 27 events per hour in the treatment arm
Promotes sustainable weight loss and overall metabolic wellness
